

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) is pleased to announce the poll results of the 2025 annual general meeting (the “**AGM**”) held at 15th Floor, Building 7, No. 6, Lane 100, Pingjiaqiao Road, Pudong New Area, Shanghai, the People's Republic of China at 2:30 p.m. on Friday, 26 June 2026. All resolutions proposed were duly passed.

Further details of the resolutions are set out in the notice of the AGM and the Company's circular dated 5 June 2026 (the “**Circular**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the AGM, (i) the total number of the issued Shares of the Company was 1,026,689,871 Shares, comprising 766,394,171 A Shares and 260,295,700 H Shares; (ii) the total number of treasury shares held by the Company was 815,871 A Shares and no voting right of treasury shares has been exercised at the AGM; (iii) there was no repurchased share which was pending cancellation and should therefore be excluded from the total number of issued shares entitling holders to attend and vote on all the resolutions at the AGM. As such, save as disclosed below, holders of 1,025,874,000 Shares (or authorized proxies) were entitled to attend and vote on the resolutions proposed at the AGM. There were no Shares entitling the Shareholders to attend and vote only against the resolutions at the AGM.

ATTENDANCE AT THE AGM

Class of Shares	Number of Shares in issue (and entitling holders to attend and vote for or against any resolution)	Number of Shares present (in person or by proxy)	Approximate %
A Shares	765,578,300	294,845,577	28.741
H Shares	260,295,700	9,145,939	0.892
Total	1,025,874,000	303,991,516	29.632

All Directors, their associates and all core connected persons of the Company have abstained from voting in favour of resolution number 5. Dr. Yao Sheng, Ms. Wang Lifang and Mr. Xiong Jun, their associates and all core connected persons of the Company have abstained from voting in favour of resolution number 11.

Save as disclosed above, to the best knowledge, information and belief of the Company: (i) there were no restrictions on any Shareholder to cast votes on any of the proposed resolutions at the AGM; (ii) no Shareholder was required under the Hong Kong Listing Rules to abstain from voting at the AGM; (iii) there were no Shares entitling the holders to attend and abstain from voting in favor of any of the proposed resolutions; and (iv) no party has stated any intention in the Circular to vote against or abstain from voting on any of the proposed resolutions.

The AGM was convened by the Board. Pursuant to Article 69 of the Articles of Association, Mr. Xiong Jun, an executive Director and chairman of the Board, presided over and chaired the AGM. All of the Directors attended the AGM.

POLL RESULTS OF THE AGM

All resolutions at the AGM were voted by registered poll. The poll results are as follows:

Ordinary resolutions ⁽¹⁾		Number of votes and percentage of the total voting shares at the AGM			Passed by Shareholders ⁽²⁾
		For	Against	Abstain	
1.	The proposal in relation to the 2025 Report of the Board of Directors	303,384,219 (99.800%)	560,750 (0.185%)	46,547 (0.015%)	YES
2.	The proposal in relation to the 2025 Annual Report and its summary	303,377,528 (99.801%)	552,341 (0.182%)	51,647 (0.017%)	YES
3.	The proposal in relation to the 2025 Profit Distribution Plan	303,356,594 (99.794%)	596,157 (0.196%)	28,765 (0.010%)	YES
4.	The proposal in relation to the application for financing and credit lines from financial institution(s) for 2026	303,001,612 (99.678%)	954,139 (0.314%)	25,765 (0.009%)	YES
5.	The proposal in relation to the remuneration of Directors for 2026	138,853,208 (99.451%)	726,982 (0.521%)	40,265 (0.029%)	YES
6.	The proposal in relation to the appointment of the PRC and overseas auditors for 2026	298,636,407 (98.242%)	5,324,844 (1.752%)	20,265 (0.007%)	YES
7.	The proposal in relation to the formulation of the Remuneration Policies of Directors and Senior Management	303,203,911 (99.744%)	740,642 (0.244%)	36,963 (0.012%)	YES
8.	The proposal in relation to the dividend distribution plan for the shareholders for the next three years (2026 to 2028)	303,385,249 (99.804%)	570,767 (0.188%)	25,500 (0.008%)	YES

Ordinary resolutions ⁽¹⁾		Number of votes and percentage of the total voting shares at the AGM			Passed by Shareholders ⁽²⁾
		For	Against	Abstain	
9.	The proposal in relation to the election of independent non-executive Director for the fourth session of the Board of Directors	303,340,327 (99.789%)	628,524 (0.207%)	12,665 (0.004%)	YES
10.	The proposal in relation to the equity changes in the implementing entity of certain investment sub-projects	303,392,155 (99.806%)	559,498 (0.184%)	29,863 (0.010%)	YES
11.	The proposal in relation to external investment and connected transaction	146,760,155 (99.569%)	597,327 (0.405%)	37,473 (0.025%)	YES

Special resolutions ⁽¹⁾		Number of votes and percentage of the total voting shares at the AGM			Passed by Shareholders ⁽²⁾
		For	Against	Abstain	
12.	The proposal in relation to the estimated external guarantee quota for 2026	293,577,491 (96.577%)	10,387,162 (3.417%)	16,863 (0.006%)	YES
13.	The proposal in relation to the grant of the general mandate to issue domestic and/or overseas debt financing instruments	294,421,863 (96.855%)	9,533,988 (3.136%)	25,665 (0.008%)	YES
14.	The proposal in relation to the general mandate to issue additional A Shares and/or H Shares	297,536,053 (97.880%)	6,412,533 (2.110%)	32,930 (0.011%)	YES

Notes:

- (1) Please refer to the Circular for details of these resolutions.
- (2) An ordinary resolution is passed by more than half of the votes casted in favor of it, and a special resolution is passed by more than two-thirds of the votes casted in favor of it.

LEGAL ADVISERS AS TO PRC LAWS

The AGM was witnessed by Jia Yuan Law Offices, the PRC legal advisers of the Company, who issued a legal opinion, pursuant to which they are of the view that the convening of and the procedures for holding the AGM, the eligibility of the convener, and attendees and the voting procedures were in compliance with the requirements of the relevant laws and regulations and the provisions of the Articles of Association and that the poll results were valid.

SCRUTINEERS

Tricor Investor Services Limited (the H share registrar of the Company), two shareholder representatives acted as the scrutineers for the vote-taking at the AGM.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 26 June 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr Yao Sheng and Mr. Tang Yi as non-executive Directors; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as Independent Non-executive Directors.

* For identification purpose only